Drugs / Spermidine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07035626 | Jun 2025 → Jun 2026 overdue | radiation-induced disorder | West China Hospital | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04405388 | Feb 2020 → Nov 2024 | hypertensive disorder | Medical University of Graz | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07662330 | Jan → Dec 2026 expected | hyperlipidemia, obesity disorder | Shanghai 10th People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spermidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07035626 ↗ |
| Known as | SPERMIDINE TRIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL19612 ↗ |
| Modality | Other / unclassified | “natural polyamine spermidine” PMID 27841876 ↗ Nov 2016 |
| Route | Oral | “given orally” NCT04405388 ↗ |